GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Context Therapeutics Inc (NAS:CNTX) » Definitions » 3-Year FCF Growth Rate

Context Therapeutics (Context Therapeutics) 3-Year FCF Growth Rate : -135.40% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Context Therapeutics 3-Year FCF Growth Rate?

Context Therapeutics's Free Cash Flow per Share for the three months ended in Dec. 2023 was $-0.45.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -135.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 5 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Context Therapeutics was -46.90% per year. The lowest was -135.40% per year. And the median was -91.15% per year.


Competitive Comparison of Context Therapeutics's 3-Year FCF Growth Rate

For the Biotechnology subindustry, Context Therapeutics's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Context Therapeutics's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Context Therapeutics's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Context Therapeutics's 3-Year FCF Growth Rate falls into.



Context Therapeutics 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Context Therapeutics  (NAS:CNTX) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Context Therapeutics 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Context Therapeutics's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Context Therapeutics (Context Therapeutics) Business Description

Traded in Other Exchanges
Address
2001 Market Street, Suite 3915, Unit No. 15, Philadelphia, PA, USA, 19103
Context Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer.
Executives
Martin A. Lehr director, officer: Chief Executive Officer 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Jennifer Lynn Minai-azary officer: Chief Financial Officer 110 MILLER AVENUE, SUITE 100, ANN ARBOR MI 48104
Alex C. Levit officer: Chief Legal Officer, Corp. Sec 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Tarek Sahmoud officer: Chief Medical Officer 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Richard J Berman director 305 COLLEGE ROAD EAST, PRINCETON NJ 08540
Jennifer Evans Stacey director AUXILIUM PHARMACEUTICALS, INC., 160 WEST GERMANTOWN PIKE, NORRISTOWN PA 19401
Linda West director C/O GALERA THERAPEUTICS, INC., 2 W LIBERTY BLVD., #110, MALVERN PA 19355
Evan G. Dick officer: SVP of R&D 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
William F. Rencher officer: Head of CMC and Regulatory 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Philip W. Kantoff director 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104

Context Therapeutics (Context Therapeutics) Headlines